Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 465

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 465
---
 a quarterly minimum royalty of $ 150,000, and (4) pursuant to the amendment thereto, (a) certain royalties at rates in the low-singledigit percentage, based on annual net sales of the Licensed Products attributable to sales of License Products in the Romeg Ex-U.S.Territory during the Romeg Ex-U.S.Territory Royalty Term and (b) a one-time, non-refundable, non-creditablepayment of $ 700,000. Pursuant to the amendment agreement, we also transferred to Romeg 779,371shares of our Common Stock. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $ 5.7million, which is comprised of the upfront license fee of $ 2.0million and deferred consideration of $ 3.7million that is the present value of the future minimum royalty payments and immaterial transaction costs. During the years ended December 31, 2024 and 2023, the Company made royalty payments in the amount of $ 0.6million and $ 0.3million, respectively. Nocontingent consideration was recognized as a liability or included in the fair value of the assets as of December 31, 2024 or December 31, 2023. ELYXYB Acquisition In February 2023, the Company entered into an asset purchase agreement (the “ELYXYB APA”) with BioDelivery Sciences International, Inc. (“BDSI”) and Collegium Pharmaceutical, Inc. (“Collegium”, and together with BDSI, the “Sellers”) to acquire the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB and its commercialization in the United States and Canada (the “ELYXYB Territory”). As consideration for the acquisition, the Company assumed various rights and obligations under the asset purchase agreement between BDSI and Dr. Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), dated August 3, 2021 (the “DRL APA”), including an irrevocable, royalty-free, exclusive license to know-howand patents of DRL related to ELYXYB and necessary or used to exploit ELYXYB in the ELYXYB Territory. No cash consideration was or will be payable to the Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include contingent sales